Cingulate Inc. Research and Development Expense
Cingulate Inc. (CING) reported Research and Development Expense of $1.49 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-13
- Cingulate Inc. research and development expense for the quarter ending 2026-06-30 was $1.49M, a 44.95% decline year-over-year.
- Cingulate Inc. research and development expense for the quarter ending 2026-03-31 was $2.18M, a 1.72% decline year-over-year.
- Cingulate Inc. research and development expense for the quarter ending 2025-12-31 was $2.00M, a 53.75% decline year-over-year.
- Cingulate Inc. research and development expense for the quarter ending 2025-09-30 was $2.85M, a 99.41% increase year-over-year.
- Cingulate Inc. research and development expense for fiscal 2025 was $9.77M, a 3.48% increase from fiscal 2024.
- Cingulate Inc. research and development expense for fiscal 2024 was $9.45M, a 39.04% decline from fiscal 2023.
- Cingulate Inc. research and development expense for fiscal 2023 was $15.49M, a 72.24% increase from fiscal 2022.
- Cingulate Inc. research and development expense for fiscal 2022 was $9.00M, a 6.95% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.49M 10-Q · filed 2026-08-13 | $3.67M 10-Q · filed 2026-08-13 | $5.67M derived: sum of 3 quarters · filed 2026-08-13 | $8.52M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $2.18M 10-Q · filed 2026-05-14 | $4.19M derived: sum of 2 quarters · filed 2026-05-14 | $7.03M derived: sum of 3 quarters · filed 2026-05-14 | $9.74M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $4.85M derived: sum of 2 quarters · filed 2026-03-18 | $7.55M derived: sum of 3 quarters · filed 2026-08-13 | $9.77M 10-K · filed 2026-03-18 |
| 2025-09-30 | $2.85M 10-Q · filed 2025-11-13 | $5.55M derived: sum of 2 quarters · filed 2026-08-13 | $7.77M 10-Q · filed 2025-11-13 | $12.10M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $2.70M 10-Q · filed 2026-08-13 | $4.92M 10-Q · filed 2026-08-13 | $9.25M derived: sum of 3 quarters · filed 2026-08-13 | $10.68M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $2.22M 10-Q · filed 2026-05-14 | $6.55M derived: sum of 2 quarters · filed 2026-05-14 | $7.98M derived: sum of 3 quarters · filed 2026-05-14 | $9.86M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $4.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $5.76M derived: sum of 2 quarters · filed 2026-03-18 | $7.64M derived: sum of 3 quarters · filed 2026-03-18 | $9.45M 10-K · filed 2026-03-18 |
| 2024-09-30 | $1.43M 10-Q · filed 2025-11-13 | $3.31M derived: sum of 2 quarters · filed 2025-11-13 | $5.12M 10-Q · filed 2025-11-13 | $10.10M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $1.88M 10-Q · filed 2025-08-19 | $3.69M 10-Q · filed 2025-08-19 | $8.67M derived: sum of 3 quarters · filed 2025-08-19 | $12.60M derived: sum of 4 quarters · filed 2025-08-19 |
| 2024-03-31 | $1.81M 10-Q · filed 2025-05-08 | $6.79M derived: sum of 2 quarters · filed 2025-05-08 | $10.72M derived: sum of 3 quarters · filed 2025-05-08 | $15.17M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $4.98M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $8.91M derived: sum of 2 quarters · filed 2025-03-27 | $13.36M derived: sum of 3 quarters · filed 2025-03-27 | $15.49M 10-K · filed 2025-03-27 |
| 2023-09-30 | $3.92M 10-Q · filed 2024-11-07 | $8.38M derived: sum of 2 quarters · filed 2024-11-07 | $10.51M 10-Q · filed 2024-11-07 | $12.44M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $4.46M 10-Q · filed 2024-08-13 | $6.58M 10-Q · filed 2024-08-13 | $8.52M derived: sum of 3 quarters · filed 2024-08-13 | $10.64M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $2.13M 10-Q · filed 2024-05-08 | $4.06M derived: sum of 2 quarters · filed 2024-05-08 | $6.18M derived: sum of 3 quarters · filed 2024-05-08 | $8.36M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $1.93M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $4.05M derived: sum of 2 quarters · filed 2024-04-01 | $6.23M derived: sum of 3 quarters · filed 2024-04-01 | $9.00M 10-K · filed 2024-04-01 |
| 2022-09-30 | $2.12M 10-Q · filed 2023-11-13 | $4.30M derived: sum of 2 quarters · filed 2023-11-13 | $7.06M 10-Q · filed 2023-11-13 | $8.33M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $2.18M 10-Q · filed 2023-08-14 | $4.94M 10-Q · filed 2023-08-14 | $6.20M derived: sum of 3 quarters · filed 2023-08-14 | $11.99M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $2.76M 10-Q · filed 2023-05-10 | $4.03M derived: sum of 2 quarters · filed 2023-05-10 | $9.82M derived: sum of 3 quarters · filed 2023-05-10 | $10.61M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $1.26M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-10 | $7.05M derived: sum of 2 quarters · filed 2023-03-10 | $7.85M derived: sum of 3 quarters · filed 2023-03-10 | $8.41M 10-K · filed 2023-03-10 |
| 2021-09-30 | $5.79M 10-Q · filed 2022-11-14 | $6.58M derived: sum of 2 quarters · filed 2022-11-14 | $7.15M 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $793.59K 10-Q · filed 2022-08-11 | $1.36M 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | $562.52K 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | $5.09M 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |